Filtered By:
Drug: Metformin
Procedure: Kidney Transplant

This page shows you your search results in order of date.

Order by Relevance | Date

Total 3 results found since Jan 2013.

Impact of Active Antihyperglycemic Components as herbal therapy for Preventive Health Care Management of Diabetes.
Abstract Diabetes is a metabolic hyperglycemic condition that progressively develops, effect small and large sensory fibers in affected population. It has various complications as hypertension, coronary artery disease, stroke, blindness, kidney disease as well as peripheral neuropathy. Sulfonylureas, thiazolidinediones, metformin, biguanidine, acarbose and insulin are commonly used drugs by diabetic patients, but these all have certain side effects. Even metformin, that is known as the miracle drug for diabetes has been found to be associated with side effects, as during treatment it involves complications with ey...
Source: Current Molecular Medicine - February 19, 2019 Category: Molecular Biology Authors: Kashyap H, Gupta S, Bist R Tags: Curr Mol Med Source Type: research

Targeting hexokinase II to mitochondria to modulate energy metabolism and reduce ischaemia‐reperfusion injury in heart
This article is part of a themed issue on Mitochondrial Pharmacology: Energy, Injury & Beyond. To view the other articles in this issue visit http://dx.doi.org/10.1111/bph.2014.171.issue‐8
Source: British Journal of Pharmacology - March 28, 2014 Category: Drugs & Pharmacology Authors: Rianne Nederlof, Otto Eerbeek, Markus W Hollmann, Richard Southworth, Coert J Zuurbier Tags: Review Source Type: research

Targeting Hexokinase II to mitochondria to modulate energy metabolism and reduce ischemia‐reperfusion injury in heart
Summary Mitochondrially‐bound hexokinase II (mtHKII) has long been known to confer cancer cells with their resilience against cell death. More recently, mtHKII has emerged as a powerful protector against cardiac cell death. mtHKII protects against IR injury in skeletal muscle and heart, attenuates cardiac hypertrophy and remodelling, and is one of the major end‐effectors through which ischemic preconditioning protects against myocardial ischemia‐reperfusion injury. Mechanisms of mtHKII cardioprotection against reperfusion injury entail the maintenance of regulated OMM permeability during ischemia and reperfusion resu...
Source: British Journal of Pharmacology - August 30, 2013 Category: Drugs & Pharmacology Authors: Rianne Nederlof, Otto Eerbeek, Markus W Hollmann, Richard Southworth, Coert J Zuurbier Tags: Review Article Source Type: research